Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Summary of Significant Accounting Policies (Details Textual)

v3.7.0.1
Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
1 Months Ended
Sep. 30, 2016
Mar. 31, 2015
Jun. 30, 2017
Dec. 31, 2016
Notes Payable, Fair Value Disclosure     $ 0  
Derivative Liability     $ 63,000 $ 63,000
Accounting Standards Update 2016-09 [Member]        
Operating Loss Carryforwards       $ 15,300,000
Nonsoftware License Arrangement [Member] | SpePharm AG [Member]        
Deferred Revenue, Additions   $ 2,000,000    
Deferred Revenue, Recognition Period   2 years    
Deferred Revenue, Revenue Recognized $ 417,000